BRIEF—Phase III cabozantinib trial meets endpoint in HCC

French drugmaker Ipsen and its US partner Exelixis have announced that the CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular carcinoma (HCC).

CELESTIAL is a randomized, global Phase III trial of cabozantinib versus placebo in patients with advanced HCC who have been previously treated with sorafenib.

The independent data monitoring committee for the study recommended that the trial should be stopped for efficacy following review of the second planned interim analysis.